On Mar. 24, 2020, PerkinElmer announced the U.S. Food and Drug Administration (FDA) had provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test.

Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) immediately began using this kit to detect SARS-CoV-2, the virus that causes COVID-19.  PerkinElmers RT-PCR test is marketed as an in vitro diagnostic (IVD) device by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD) and was available in over 30 countries worldwide.